{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:37:48Z","timestamp":1788435468795,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T00:00:00Z","timestamp":1717459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Sanofi and Regeneron Pharmaceuticals, Inc"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Prurigo nodularis (PN) is a pruritic skin disease characterized by multiple intensely itchy skin nodules in symmetrically distributed areas of the extremities. There are limited studies on the epidemiology and treatment pathways of PN, especially moderate-to-severe PN, from England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the epidemiology and treatment pathways of mild and moderate-to-severe PN in England.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study used data from the Clinical Practice Research Datalink and Hospital Episode Statistics in England. Adult patients (aged \u2265 18 years) with a PN-specific diagnosis code allocated any time between 1 April 2007 and 1 March 2019 (patient identification period) were selected. Patients were included if their first PN diagnostic code (index diagnosis date; IDD) was recorded during the identification period, with data available 6 months before and \u2265 12 months after the IDD. Patients were classified as having moderate-to-severe PN (MSPN) or mild PN (MiPN), based on the presence or absence of a prescription record, post-IDD, for either a systemic immunosuppressant or a gabapentinoid. Patients with MSPN and MiPN were matched 1 : 1 according to age, sex and IDD. Prevalence and incidence were calculated for each year from 2007 to 2019. Drugs prescribed post-IDD were analysed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 8933 patients (MSPN, n = 2498; MiPN, n = 6435) were included in the study; 2462 patients with MiPN and 2462 with MSPN were included for the comparative analysis. The presence of atopic dermatitis, asthma and eosinophilic oesophagitis were significantly higher (all P &amp;lt; 0.001) in patients with MSPN compared with those with MiPN. The overall prevalence of cases of PN increased during the study period. The incidence rate also showed a similar trend. The rates of prescription of potent and super-potent topical corticosteroids (TCS), topical calcineurin inhibitors, first- and second-generation antihistamines, oral and injectable systemic corticosteroids, methotrexate, antidepressants and tacrolimus were significantly higher (all P &amp;lt; 0.001) in patients with MSPN compared with those with MiPN.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The epidemiology of PN was consistent with that found in other European studies. Patients with MSPN received a significantly higher number of prescriptions for potent TCS and systemic drugs compared with patients with MiPN.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae207","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T01:26:23Z","timestamp":1717550783000},"page":"548-555","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis"],"prefix":"10.1093","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9887-8159","authenticated-orcid":false,"given":"Donia","family":"Bahloul","sequence":"first","affiliation":[{"name":"Sanofi , Gentilly , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hudson","sequence":"additional","affiliation":[{"name":"Sanofi , Reading , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orsolya","family":"Balogh","sequence":"additional","affiliation":[{"name":"Sanofi , Reading , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elgan","family":"Mathias","sequence":"additional","affiliation":[{"name":"Human Data Sciences , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Heywood","sequence":"additional","affiliation":[{"name":"Human Data Sciences , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hubbuck","sequence":"additional","affiliation":[{"name":"Human Data Sciences , Cardiff , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyinye","family":"Diribe","sequence":"additional","affiliation":[{"name":"Sanofi , Reading , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"McDonald","sequence":"additional","affiliation":[{"name":"Sanofi , Reading , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Bewley","sequence":"additional","affiliation":[{"name":"Dermatology Department, Royal London Hospital, Barts Health NHS Trust , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,4]]},"reference":[{"key":"2024091723513341800_ljae207-B1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723513341800_ljae207-B2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","article-title":"Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus","volume":"84","author":"Elmariah","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2024091723513341800_ljae207-B3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ejp.767","article-title":"The pathogenesis of prurigo nodularis \u2013 \u2018Super-Itch\u2019 in exploration","volume":"20","author":"Zeidler","year":"2016","journal-title":"Eur J Pain"},{"key":"2024091723513341800_ljae207-B4","doi-asserted-by":"crossref","first-page":"1022889","DOI":"10.3389\/fmed.2022.1022889","article-title":"Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis","volume":"9","author":"Deng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024091723513341800_ljae207-B5","doi-asserted-by":"crossref","first-page":"1011142","DOI":"10.3389\/fmed.2022.1011142","article-title":"Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: a cluster analysis","volume":"9","author":"Parthasarathy","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2024091723513341800_ljae207-B6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","article-title":"Ethnic differences and comorbidities of 909 prurigo nodularis patients","volume":"79","author":"Boozalis","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2024091723513341800_ljae207-B7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/jcm11010095","article-title":"Epidemiology, comorbidities, and prescription patterns of Korean prurigo nodularis patients: a multi-institution study","volume":"11","author":"Woo","year":"2021","journal-title":"J Clin Med"},{"key":"2024091723513341800_ljae207-B8","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","article-title":"Health-related quality of life and economic burden of prurigo nodularis","volume":"86","author":"Whang","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2024091723513341800_ljae207-B9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/09546634.2013.814759","article-title":"Prurigo nodularis: an update on etiopathogenesis and therapy","volume":"24","author":"Fostini","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"2024091723513341800_ljae207-B10","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/jdv.15107","article-title":"Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723513341800_ljae207-B11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.det.2018.02.003","article-title":"Prurigo nodularis and its management","volume":"36","author":"Zeidler","year":"2018","journal-title":"Dermatol Clin"},{"key":"2024091723513341800_ljae207-B12","first-page":"e414-31","article-title":"guidelines for the\u00a0\u00addiagnosis and treatment of prurigo","volume":"48","author":"Satoh","year":"2020","journal-title":"J Dermatol"},{"key":"2024091723513341800_ljae207-B13","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI-guideline on chronic prurigo including prurigo nodularis","volume":"5","author":"St\u00e4nder","year":"2020","journal-title":"Itch"},{"key":"2024091723513341800_ljae207-B14","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jdv.15040","article-title":"Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo","volume":"32","author":"Polking","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024091723513341800_ljae207-B15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa1908316","article-title":"Trial of nemolizumab in \u00admoderate-to-severe prurigo nodularis","volume":"382","author":"Stander","year":"2020","journal-title":"N Engl J Med"},{"key":"2024091723513341800_ljae207-B16","author":"Kwatra"},{"key":"2024091723513341800_ljae207-B17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CCID.S188070","article-title":"Treatment-resistant prurigo nodularis: challenges and solutions","volume":"12","author":"Kowalski","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2024091723513341800_ljae207-B18","author":"U.S. Food & Drug Administration"},{"key":"2024091723513341800_ljae207-B19","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3655","article-title":"Epidemiology of prurigo nodularis compared with psoriasis in Germany: a claims database analysis","volume":"100","author":"Stander","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2024091723513341800_ljae207-B20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/bjd.21032","article-title":"Epidemiology of prurigo nodularis in England: a retrospective database analysis","volume":"187","author":"Morgan","year":"2022","journal-title":"Br J Dermatol"},{"key":"2024091723513341800_ljae207-B21","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3518","article-title":"Prevalence of prurigo nodularis in Poland","volume":"100","author":"Ryczek","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2024091723513341800_ljae207-B22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2024091723513341800_ljae207-B23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jdin.2020.10.009","article-title":"Prevalence of prurigo nodularis in the United States of America: a retrospective database analysis","volume":"2","author":"Stander","year":"2021","journal-title":"JAAD Int"},{"key":"2024091723513341800_ljae207-B24","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2024091723513341800_ljae207-B25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3414\/ME11-02-0023","article-title":"Snomed CT implementation","volume":"51","author":"H\u00f8jen","year":"2012","journal-title":"Methods Inf Med"},{"key":"2024091723513341800_ljae207-B26","author":"Bahloul"},{"key":"2024091723513341800_ljae207-B27","article-title":"[Efficacy and safety of topical 0.05% diflorasone diacetate (florone) cream\/ointment in patients with acute\/chronic dermatitis]","volume":"59","author":"Schneider","year":"1984","journal-title":"Z Hautkr"},{"key":"2024091723513341800_ljae207-B28","first-page":"221","article-title":"Prurigo nodularis: picking the right treatment","volume":"65","author":"Saco","year":"2015","journal-title":"J Fam Pract"},{"key":"2024091723513341800_ljae207-B29","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2147\/CCID.S208964","article-title":"Treatment-resistant prurigo nodularis","volume":"12","author":"Kolli","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2024091723513341800_ljae207-B30","first-page":"e414-31","article-title":"guidelines for the diagnosis and treatment of prurigo","volume":"48","author":"Satoh","year":"2020","journal-title":"J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae207\/58524607\/ljae207.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/548\/59122401\/ljae207.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/191\/4\/548\/59122401\/ljae207.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T23:51:49Z","timestamp":1726617109000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/191\/4\/548\/7687619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,4]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,6,4]]},"published-print":{"date-parts":[[2024,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae207","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,6,4]]}}}